Traws Pharma Inc
trawspharma.comWhat Do They Do?
Develops investigational antiviral drugs for respiratory viral diseases, including influenza and COVID, alongside cancer drug candidates for solid tumors and blood cancers.
10-K for FY2024, filed Apr 15, 2026
How Do They Make Money?
Traws earns money by licensing product-candidate rights to partners, with upfront fees when rights are transferred, milestone payments tied to development or regulatory progress, and royalties when licensed products are sold.
10-K for FY2024, filed Apr 15, 2026The Company enters into licensing and collaboration agreements, under which it licenses certain of its product candidates’ rights to third…View ↗
Licensing of Intellectual Property: If the license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the…View ↗
$2.8M
-
10-K for FY2024, filed Apr 15, 2026
$2.8M ↗
Who Are Their Customers?
Third parties obtain rights to product candidates through licensing and collaboration agreements.
10-K for FY2024, filed Apr 15, 2026The Company enters into licensing and collaboration agreements, under which it licenses certain of its product candidates’ rights to third…View ↗
Do Revenues Turn Into Profits?
Yes. Its net income in FY2024 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$20.8M.
10-K for FY2024, filed Apr 15, 2026
−$17.9MView ↗
10-K for FY2024, filed Apr 15, 2026
$9.2MView ↗
10-K for FY2024, filed Apr 15, 2026
−$20.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.1MView ↗
- ▲ +234% (Loss)
- vs −$915K in Q2 FY2025
-
Jul 31, 2026
Nasdaq cited a minimum bid-price deficiency
The listing remains effective while the company has until January 25, 2027 to regain compliance.
Sources
8-K, filed Jul 31, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from July 29, 2026 or until January 25…View ↗
Growing. Revenue grew 12.3x in 4 years, from $226K in FY2020 to $2.8M in FY2024, about 87% a year.
Added antiviral development
The business expanded beyond cancer drug development to include antiviral candidates for respiratory viral diseases, while its cancer programs continued.
10-K for FY2021, filed Mar 21, 2022 10-K for FY2024, filed Apr 15, 2026Onconova Therapeutics, Inc., sometimes referred to as “we” or the “Company,” is a clinical-stage biopharmaceutical company focused on…View ↗
On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger (the “Merger”) with Trawsfynydd…View ↗
Who Do They Compete With?
Competes with Gilead, Glaxo SmithKline, BioCryst, Roche, Cidara, Eradivir, Pfizer, Merck, Ridgeback, Novartis, and Eli Lilly
10-K for FY2024, filed Apr 15, 2026There are currently various drugs approved for the treatment of influenza, including without limitation the neuraminidase inhibitors…View ↗
Loading...
